Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics (CORT)
:CORT
CORT Stock Chart & Stats
$72.52
$0.08(0.16%)
At close: 4:00 PM EST
$72.52
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$42.01 - $117.33
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.02M
Market Cap
$7.64B
Enterprise Value$8.51B
Total Cash (Recent Filing)$342.23M
Total Debt (Recent Filing)$6.61M
Price to Earnings (P/E)64.5
Beta0.41
Next Earnings
Oct 29, 2025EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding105,371,730
10 Day Avg. Volume982,874
30 Day Avg. Volume1,018,256
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue11.88
Enterprise Value/Gross Profit12.08
Enterprise Value/Ebitda81.93
Forecast
1Y Price Target
$135.33Price Target Upside86.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Business Model StrengthThe feedback has been overwhelmingly positive and the company's business model is as strong as ever.
Clinical Trial SuccessRelacorilant demonstrates strong efficacy in PARPi exposed PROC patients.
Regulatory ApprovalAnalyst remains confident that relacorilant is likely to receive the FDA approval for the treatment of platinum-resistant ovarian cancer.
Bears Say
Distribution ChallengesThe departure of Optime Care as a distributor of Korlym causes a delay in Corcept's strategy to have two pharmacies operational, which may lead to near-term sales headwinds.
Sales ProjectionsThe company is lowering its sales projections for Korlym due to the disruption in distribution, with a reduction in 2025 sales estimates.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $42.01 and its highest was $117.33 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $7.64B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is tomorrow.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Jul 31, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.188 by $0.102.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.13.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 105,371,730 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of $0.29 in its last earnings report, beating expectations of $0.188. Following the earnings report the stock price went up 2.724%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$135.33 (86.61% Upside)
$135.33 (86.61% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 197.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $165.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 14.8%
Last 30 Days ▲ 14.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.51%
12-Months-Change
Fundamentals
Return on Equity
21.42%
Trailing 12-Months
Asset Growth
12.20%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies that treat serious metabolic and psychiatric disorders by modulating the effects of cortisol, a hormone involved in stress response. The company's lead product, Korlym (mifepristone), is approved for the treatment of Cushing's syndrome, a condition characterized by excessive cortisol levels. Corcept is also engaged in developing additional products aimed at addressing various conditions related to cortisol dysregulation.
CORT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, significant increases in prescriptions and market expansion, and successful clinical trial results. However, the call also noted challenges, such as a slight decline in net income, pharmacy capacity issues affecting revenue, and ongoing patent litigation. Despite these challenges, the overall sentiment leans positive due to promising trial results and strategic expansions.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$135.33
▲(86.61% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
11.45% Insiders
17.35% Mutual Funds
<0.01% Other Institutional Investors
50.44% Public Companies and Individual Investors